TapewireFind a company

person · Reporting owner

Sun Elaine D

Disclosed activity across 3 companies

Tapewire entity
36348
SEC CIK
0001805339

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HALOZYME THERAPEUTICS, INC.HALO · Entity 793SVP, Chief Financial OfficerApril 01, 2021April 01, 2021
RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008DirectorJune 17, 2026June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HALOZYME THERAPEUTICS, INC.

Report date April 01, 2021 · Filed April 01, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,018 Ending reported balance After 2021-04-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2021-04-01 · Exercise / conversion · Acquired 10,196 · Balance 18,077

Row 2 · 2021-04-01 · Tax withholding · Disposed 4,059 · Balance 14,018

F1: The reported disposition of 4,059 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.

Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct30,600 Reported balance After 2021-04-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-04-01 · Exercise / conversion · Disposed 10,196 · Balance 30,600

F2: Each earned Performance Stock Unit (PSU) is settled by delivery of one share of common stock. The vesting of these PSUs was subject to the satisfaction of both performance-based and time-based vesting conditions. The performance-based condition was satisfied as to 25% of the total PSU grant upon achievement of each of four separate milestones of 20%, 30%, 40% and 50% average increases over 20 consecutive trading days of the closing price of the Issuer's common stock on the date of grant. The time-based condition will be satisfied as to 25% of the total PSU grant upon each of the first four anniversaries of the date of grant contingent upon the Reporting Person's continued service to the Issuer through each such anniversary date. Subject to the terms of the PSU award agreement, the performance-based conditions of the PSU grant were certified as satisfied on July 2, 2020. Therefore, vesting of these PSUs remains subject only to the time-based vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: The reported disposition of 4,059 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.

F2: Each earned Performance Stock Unit (PSU) is settled by delivery of one share of common stock. The vesting of these PSUs was subject to the satisfaction of both performance-based and time-based vesting conditions. The performance-based condition was satisfied as to 25% of the total PSU grant upon achievement of each of four separate milestones of 20%, 30%, 40% and 50% average increases over 20 consecutive trading days of the closing price of the Issuer's common stock on the date of grant. The time-based condition will be satisfied as to 25% of the total PSU grant upon each of the first four anniversaries of the date of grant contingent upon the Reporting Person's continued service to the Issuer through each such anniversary date. Subject to the terms of the PSU award agreement, the performance-based conditions of the PSU grant were certified as satisfied on July 2, 2020. Therefore, vesting of these PSUs remains subject only to the time-based vesting conditions.

RECURSION PHARMACEUTICALS, INC.

Report date June 17, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect135,981 Reported balance After 2026-06-17 transaction · row 1
1 source row

Row 1 · 2026-06-17 · Grant · Acquired 88,424 · Balance 135,981

F1: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

DYNAVAX TECHNOLOGIES CORP

Report date February 10, 2026 · Filed February 10, 2026

Section 16 reporting ended · disclosed 2026-02-10. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock - Restricted Stock UnitsSEC Table I · non-derivativeDirect0 Reported balance After 2026-02-10 transaction · row 1
1 source row

Row 1 · 2026-02-10 · Disposition to issuer · Disposed 29,865 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.33Direct0 Reported balance After 2026-02-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-02-10 · Disposition to issuer · Disposed 45,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.68Direct0 Reported balance After 2026-02-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-10 · Disposition to issuer · Disposed 11,250 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.20Direct0 Reported balance After 2026-02-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-02-10 · Disposition to issuer · Disposed 22,500 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85Direct0 Reported balance After 2026-02-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-02-10 · Disposition to issuer · Disposed 22,500 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.18Direct0 Reported balance After 2026-02-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-02-10 · Disposition to issuer · Disposed 28,500 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price.

F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 17, 2026 Filed Jun 22, 2026 20:32 UTC RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 GrantClass A Common Stock 88,424 $0.00 $0.00
Disclosure

SEC source: 0001601830-26-000085 · wk-form4_1782160336.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,981

F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
February 10, 2026 Filed Feb 10, 2026 16:15 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 Disposition to issuerStock Option (Right to Buy) · Derivative 28,500 Not disclosed Strike: $10.18 Not disclosed
Disclosure

SEC source: 0001805339-26-000002 · form4-02102026_040207.xml · derivative · entry 6

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Read SEC document
February 10, 2026 Filed Feb 10, 2026 16:15 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 Disposition to issuerStock Option (Right to Buy) · Derivative 22,500 Not disclosed Strike: $11.85 Not disclosed
Disclosure

SEC source: 0001805339-26-000002 · form4-02102026_040207.xml · derivative · entry 5

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Read SEC document
February 10, 2026 Filed Feb 10, 2026 16:15 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 Disposition to issuerStock Option (Right to Buy) · Derivative 22,500 Not disclosed Strike: $11.20 Not disclosed
Disclosure

SEC source: 0001805339-26-000002 · form4-02102026_040207.xml · derivative · entry 4

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Read SEC document
February 10, 2026 Filed Feb 10, 2026 16:15 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 Disposition to issuerStock Option (Right to Buy) · Derivative 11,250 Not disclosed Strike: $11.68 Not disclosed
Disclosure

SEC source: 0001805339-26-000002 · form4-02102026_040207.xml · derivative · entry 3

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Read SEC document
February 10, 2026 Filed Feb 10, 2026 16:15 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 Disposition to issuerStock Option (Right to Buy) · Derivative 45,000 Not disclosed Strike: $13.33 Not disclosed
Disclosure

SEC source: 0001805339-26-000002 · form4-02102026_040207.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.

Read SEC document
February 10, 2026 Filed Feb 10, 2026 16:15 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 Disposition to issuerCommon Stock - Restricted Stock Units 29,865 Not disclosed Not disclosed
Disclosure

SEC source: 0001805339-26-000002 · form4-02102026_040207.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:22 UTC RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 GrantStock Option (Right to Buy) · Derivative 22,016 $0.00 Strike: $5.11 $0.00
Disclosure

SEC source: 0001601830-25-000106 · wk-form4_1750713747.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,016

Underlying: Class A Common Stock · 22,016 shares

Expires 2035-06-18

F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:22 UTC RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 GrantClass A Common Stock 11,008 $0.00 $0.00
Disclosure

SEC source: 0001601830-25-000106 · wk-form4_1750713747.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,557

F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
June 11, 2025 Filed Jun 13, 2025 17:44 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantStock Option (Right to Buy) · Derivative 28,500 $0.00 Strike: $10.18 $0.00
Disclosure

SEC source: 0001029142-25-000095 · wk-form4_1749851072.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Commont Stock · 28,500 shares

Expires 2032-06-10

F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.

Read SEC document
June 11, 2025 Filed Jun 13, 2025 17:44 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantCommon Stock 5,758 $0.00 $0.00
Disclosure

SEC source: 0001029142-25-000095 · wk-form4_1749851072.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,865

F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:27 UTC RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 GrantStock Option (Right to Buy) · Derivative 73,099 $0.00 Strike: $6.84 $0.00
Disclosure

SEC source: 0001601830-25-000047 · wk-form4_1742416029.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,099

Underlying: Class A Common Stock · 73,099 shares

Expires 2035-03-17

F2 · derivative.exercise_date: Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:27 UTC RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 GrantClass A Common Stock 36,549 $0.00 $0.00
Disclosure

SEC source: 0001601830-25-000047 · wk-form4_1742416029.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,549

F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:19 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantStock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $11.85 $0.00
Disclosure

SEC source: 0000950170-24-065573 · ownership.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2031-05-22

F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:19 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantCommon Stock 5,357 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-065573 · ownership.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,107

F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company.

Read SEC document
May 26, 2023 Filed May 31, 2023 17:34 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantStock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $11.20 $0.00
Disclosure

SEC source: 0001209191-23-033176 · doc4.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-05-25

F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.

Read SEC document
May 26, 2023 Filed May 31, 2023 17:34 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantCommon Stock 5,357 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-033176 · doc4.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,750

F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. The reporting person has reported prior awards of restricted stock units in Table II on Form 4. The total reported in Column 5 includes 5,357 newly awarded restricted stock units and 13,393 restricted stock units previously reported in Table II.

Read SEC document
May 26, 2022 Filed May 27, 2022 17:01 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantStock Option (Right to Buy) · Derivative 11,250 Not disclosed Strike: $11.68 Not disclosed
Disclosure

SEC source: 0001209191-22-032619 · doc4.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2029-05-25

F3 · price: Not applicable.

F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.

Read SEC document
May 26, 2022 Filed May 27, 2022 17:01 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantRestricted Stock Unit · Derivative 2,679 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-032619 · doc4.xml · derivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,679

Underlying: Common Stock · 2,679 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company.

F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company.

F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company.

Read SEC document
December 10, 2021 Filed Dec 14, 2021 19:23 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $13.33 $0.00
Disclosure

SEC source: 0001209191-21-069621 · doc4.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2028-12-09

F2 · derivative.exercise_date: This option grant vests over three years with 1/3 vesting on each annual anniversary of December 10, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date.

Read SEC document
December 10, 2021 Filed Dec 14, 2021 19:23 UTC DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 GrantRestricted Stock Unit · Derivative 10,714 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-069621 · doc4.xml · derivative · entry 1

Sun Elaine D · CIK 0001805339 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,714

Underlying: Common Stock · 10,714 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of December 10, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of December 10, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company.

F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of December 10, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company.

F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of December 10, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company.

Read SEC document
April 01, 2021 Filed Apr 1, 2021 23:43 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionPerformance Stock Units · Derivative 10,196 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001179110-21-003974 · edgar.xml · derivative · entry 3

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,600

Underlying: Common Stock · 10,196 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Each earned Performance Stock Unit (PSU) is settled by delivery of one share of common stock. The vesting of these PSUs was subject to the satisfaction of both performance-based and time-based vesting conditions. The performance-based condition was satisfied as to 25% of the total PSU grant upon achievement of each of four separate milestones of 20%, 30%, 40% and 50% average increases over 20 consecutive trading days of the closing price of the Issuer's common stock on the date of grant. The time-based condition will be satisfied as to 25% of the total PSU grant upon each of the first four anniversaries of the date of grant contingent upon the Reporting Person's continued service to the Issuer through each such anniversary date. Subject to the terms of the PSU award agreement, the performance-based conditions of the PSU grant were certified as satisfied on July 2, 2020. Therefore, vesting of these PSUs remains subject only to the time-based vesting conditions.

F2 · derivative.expiration_date: Each earned Performance Stock Unit (PSU) is settled by delivery of one share of common stock. The vesting of these PSUs was subject to the satisfaction of both performance-based and time-based vesting conditions. The performance-based condition was satisfied as to 25% of the total PSU grant upon achievement of each of four separate milestones of 20%, 30%, 40% and 50% average increases over 20 consecutive trading days of the closing price of the Issuer's common stock on the date of grant. The time-based condition will be satisfied as to 25% of the total PSU grant upon each of the first four anniversaries of the date of grant contingent upon the Reporting Person's continued service to the Issuer through each such anniversary date. Subject to the terms of the PSU award agreement, the performance-based conditions of the PSU grant were certified as satisfied on July 2, 2020. Therefore, vesting of these PSUs remains subject only to the time-based vesting conditions.

Read SEC document
April 01, 2021 Filed Apr 1, 2021 23:43 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 4,059 $42.43 $172,223.37
Disclosure

SEC source: 0001179110-21-003974 · edgar.xml · nonDerivative · entry 2

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,018

F1 · shares: The reported disposition of 4,059 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.

Read SEC document
April 01, 2021 Filed Apr 1, 2021 23:43 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,196 $0.00 $0.00
Disclosure

SEC source: 0001179110-21-003974 · edgar.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,077

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 00:15 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 12,166 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001179110-21-002560 · edgar.xml · derivative · entry 3

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,496

Underlying: Common Stock · 12,166 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 00:15 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 4,285 $45.01 $192,867.85
Disclosure

SEC source: 0001179110-21-002560 · edgar.xml · nonDerivative · entry 2

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,881

F1 · shares: The reported disposition of 4,285 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 00:15 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 12,166 $0.00 $0.00
Disclosure

SEC source: 0001179110-21-002560 · edgar.xml · nonDerivative · entry 1

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 15, 2021 Filed Feb 17, 2021 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock Units · Derivative 14,898 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001179110-21-001808 · edgar.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,898

Underlying: Common Stock · 14,898 shares

Expires not disclosed

F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

Read SEC document
February 15, 2021 Filed Feb 17, 2021 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 25,642 $0.00 Strike: $49.84 $0.00
Disclosure

SEC source: 0001179110-21-001808 · edgar.xml · derivative · entry 1

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,642

Underlying: Common Stock · 25,642 shares

Expires 2031-02-15

F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 20:56 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantPerformance Stock Units · Derivative 40,796 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001179110-20-004645 · edgar.xml · derivative · entry 1

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,796

Underlying: Common Stock · 40,796 shares

Expires not disclosed

F1 · derivative.exercise_date: The vesting of these Performance Stock Units (PSUs) is subject to the satisfaction of both performance-based and time-based vesting conditions. The performance-based condition will be satisfied as to 25% of the total PSU grant upon achievement of each of four separate milestones of 20%, 30%, 40% and 50% increases of the closing price of the Issuer's common stock on the date of grant. The PSUs may be earned at any point during the three-year performance period (commencing on the date of grant) and any PSUs that are not earned during the three-year performance period will be forfeited. The time-based condition will be satisfied as to 25% of the total PSU grant upon each of the first four anniversaries of the date of grant contingent upon the Reporting Person's continued service to the Issuer through each such anniversary date.

F1 · derivative.expiration_date: The vesting of these Performance Stock Units (PSUs) is subject to the satisfaction of both performance-based and time-based vesting conditions. The performance-based condition will be satisfied as to 25% of the total PSU grant upon achievement of each of four separate milestones of 20%, 30%, 40% and 50% increases of the closing price of the Issuer's common stock on the date of grant. The PSUs may be earned at any point during the three-year performance period (commencing on the date of grant) and any PSUs that are not earned during the three-year performance period will be forfeited. The time-based condition will be satisfied as to 25% of the total PSU grant upon each of the first four anniversaries of the date of grant contingent upon the Reporting Person's continued service to the Issuer through each such anniversary date.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock Units · Derivative 48,662 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001179110-20-003052 · edgar.xml · derivative · entry 2

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,662

Underlying: Common Stock · 48,662 shares

Expires 2030-03-02

F2 · derivative.exercise_date: This restricted stock unit grant vests one-fourth on such date and then one-fourth on each anniversary thereafter.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 104,969 $0.00 Strike: $20.55 $0.00
Disclosure

SEC source: 0001179110-20-003052 · edgar.xml · derivative · entry 1

Sun Elaine D · CIK 0001805339 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,969

Underlying: Common Stock · 104,969 shares

Expires 2030-03-02

F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.